Droplet Genomics - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 65,234 | 150,220 | 124,694 | 870,777 | 1,931,408 | 2,845,771 | 3,689,650 | 2,291,957 |
| Profit before tax | - | - | - | 57,870 | -34,810 | -1,429,854 | -835,007 | -5,258,471 |
| Net profit | 472 | 16,669 | -314,333 | 57,870 | -34,810 | -1,429,854 | -835,007 | -5,258,471 |
| Equity | 61,046 | 77,715 | -236,618 | -178,748 | 878,566 | 3,628,287 | 4,141,797 | 4,672,313 |
| Liabilities | 11,531 | 65,004 | 645,145 | 1,176,255 | 4,193,960 | 289,738 | 637,290 | 799,681 |
| Non-current assets | 4,447 | 2,794 | 130,012 | 214,146 | 381,529 | 449,032 | 494,690 | 2,043,841 |
| Current assets | 68,130 | 139,925 | 293,805 | 834,640 | 4,705,688 | 3,596,593 | 4,419,344 | 3,588,050 |
| Total assets | 72,577 | 142,719 | 423,817 | 1,048,786 | 5,087,217 | 4,045,625 | 4,914,034 | 5,631,891 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 173,834 | 300,040 | 182,140 |
| Social insurance contributions | - | - | - | - | - | 486,044 | 563,626 | 817,479 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -24.1% | +130.3% | -17.0% | +598.3% | +121.8% | +47.3% | +29.7% | -37.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.7% | 11.7% | -74.2% | 5.5% | -0.7% | -35.3% | -17.0% | -93.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.8% | 21.4% | - | - | -4.0% | -39.4% | -20.2% | -112.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.7% | 11.1% | -252.1% | 6.6% | -1.8% | -50.2% | -22.6% | -229.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | 6.6% | -1.8% | -50.2% | -22.6% | -229.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | 0.8 | - | - | 4.8 | 0.1 | 0.2 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 6,927 | 13,353 | 8,649 | 42,134 | 65,844 | 55,891 | 62,273 | 30,903 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Droplet Genomics - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-10-23 | 2025-11-02 | 0.19 |
| 2025-10-16 | 2025-10-21 | 16.66 |
| 2025-09-16 | 2025-09-22 | 90.00 |
Droplet Genomics - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Droplet Genomics, UAB (code 304269855) is a Private Limited Liability Company operating in research and experimental development on other natural sciences and engineering. In 2025, revenue amounted to €2.29 million, down 37.9% year on year and 19.5% below the 2023 level. The company remained loss-making, posting a net loss of €5.26 million in 2025, compared with €835.0 thousand in 2024 and €1.43 million in 2023. The 2025 profit margin was -229.4%, reflecting the size of the loss relative to revenue. Over the three-year period, revenue increased from €2.85 million in 2023 to €3.69 million in 2024 before declining in 2025, while losses narrowed in 2024 and then widened sharply in 2025. Total assets reached €5.63 million in 2025, supported by equity of €4.67 million and liabilities of €799.7 thousand. The equity ratio was 83.0% and debt-to-equity 0.17, indicating a lightly leveraged balance sheet. Long-term assets increased to €2.04 million, and asset turnover stood at 0.41x. Revenue per employee was €31.0 thousand.